StockData
Anixa Biosciences Inc logo

Anixa Biosciences Inc (ANIX) company profile

ANIXNasdaqPharmaceutical PreparationsFiscal year ends October 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 9, 2026Score 6/30
$2.67+0.12 (+4.71%)

Close on Nov 17, 2026Market cap $92.82MP/E –Yield –

About Anixa Biosciences

Pharmaceutical Preparations, SIC 2834

Anixa Biosciences, Inc. is a biotechnology company focused on developing therapies and vaccines to address critical unmet needs in oncology. The company's therapeutics portfolio includes liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy targeting ovarian cancer that is being developed through its Certainty Therapeutics subsidiary in collaboration with the Moffitt Cancer Center. Its vaccine programs feature an investigational breast cancer vaccine targeting alpha-lactalbumin, developed alongside the Cleveland Clinic, as well as an ovarian cancer vaccine targeting the anti-Mullerian hormone receptor 2 protein extracellular domain. Anixa also conducts discovery work to identify vaccine targets for lung, colon, and prostate cancers.

The company operates from its principal executive offices located in San Jose, California. Clinical and pre-clinical development activities take place in the United States in partnership with research organizations including the Cleveland Clinic, Moffitt Cancer Center, and the National Cancer Institute. Outside its core oncology programs, Anixa maintains limited patent licensing activities from legacy operations.

Summary of the business section of Anixa Biosciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Anixa Biosciences Inc
Founded
1982
Headquarters
San Jose, CA
Address
3150 Almaden Expressway, Suite 250 95118
Phone
(408) 708-9808
Website
anixa.com
Employees
4, Oct 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
October 31
Auditor
HASKELL & WHITE LLP, Irvine, California

Stock & identifiers

Ticker
ANIX
Exchange
Nasdaq
IPO date
Oct 7, 1983
Shares outstanding
35M, Sep 9, 2026
Public float
$85.12M, Apr 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-25 reverse, Jun 26, 2015; 2-for-1, Jun 18, 1996; 2-for-1, Mar 19, 1991; 5-for-4, Sep 16, 1987; 3-for-1, Nov 12, 1985
SEC CIK
715446
CUSIP
03528H109
ISIN
US03528H1095
FIGI
BBG000BG3J79
Share class FIGI
BBG001S5Q1P7
LEI
549300PW2C2QTAJL2D19
EIN
11-2622630

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Amit KumarChief Executive Officer, Director685,000
Michael CatelaniPresident, COO, & CFO50,000
Lewis H. Titterton jrDirector1,054,003
Arnold M. BaskiesDirector140,572
Emily GottschalkDirector45,665

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$2.55M$3.71M$1.30M$74$137
FY2024$3.48M$3.13M$1.76M$63$118
FY2023$3.64M-$2.62M$1.97M$56$81
FY2022$2.16M$4.77M$1.85M$117$66

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsOtherTotalvs. prior year
Dr. Amit Kumar
Chairman of the Board and Chief Executive Officer
$815.17K$500.00K$1.13M$102.41K$2.55M-27%
Michael J. Catelani
President, Chief Operating Officer and Chief Financial Officer
$553.16K$150.00K$564.55K$31.00K$1.30M-26%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of October 31, 2025, we had four full-time employees working for our Company and subsidiaries.”

Corporate history

Events identified from SEC filings

DateEventDetails
Sep 27, 2018Name changeName changed from ITUS Corp to Anixa Biosciences Inc
Aug 24, 2017Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 26, 2016Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 9, 2015ListingRegistration of securities on an exchange (Form 8-A)
Jul 9, 2015Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 27, 2014Name changeName changed from COPYTELE INC to ITUS Corp
May 10, 2013Auditor changeChange in certifying accountant (8-K Item 4.01)
Jan 31, 2011Late filingNotification of late filing
Aug 17, 2009Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 10, 2009Late filingNotification of late filing
Jan 15, 2009Late filingNotification of late filing
Sep 10, 2008Late filingNotification of late filing
Mar 12, 2008Late filingNotification of late filing
Jan 15, 2008Late filingNotification of late filing
Dec 27, 2007Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 11, 2007Late filingNotification of late filing
Jan 17, 2006Late filingNotification of late filing
Jan 18, 2005Late filingNotification of late filing
Jan 29, 2003Late filingNotification of late filing

See a number that looks wrong?